Skip to content



Eisai sponsored session - Thursday 18th March - 1600-1630

Optimising remote consultations - a new era of patient care
Chair: Prof Rob Duncombe, Director of Pharmacy, The Christie
Dr Paul Ross, Kings College Hospital and Donna O'Sullivan, CNS, Royal Free Hospital



Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including oncology and neurology. As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries. For more information about Eisai, please visit

Roche sponsored session- Thursday 18th March- 1310-1340

Who should be considered for 1L systemic combination treatment for advanced or unresectable HCC?                                                                       Dr Tim Cross and Dr Paul Ross

Roche is a pioneer in pharmaceuticals and diagnostics, focused on advancing science to improve people’s lives. We have created truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. In the UK we employ over 2,000 people who work hard every day to bring our medicines and diagnostics to people who urgently need them. We work from bench to bedside - researching new medicines and diagnostics, running global clinical trials, and collaborating with the NHS to try to ensure rapid uptake and delivery of our products and services. For more information:

Sirtex sponsored session - Friday 19th March - 1240-1310

Advances in SIR-Spheres® therapy for HCC

Latest update for the place of SIRT in HCC
Dr Abid Suddle–Institute of Liver Studies, King's College Hospital (London)

Evolving the treatment of HCC with SIR-Spheres
Dr Damian Mullan & Dr Pavan Najran - Radiology, The Christie Hospital (Manchester)


Sirtex Medical is a global healthcare business with offices in the US, Australia, Germany and Singapore, working to improve outcomes in people with cancer.

Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres.

SIR-Spheres is a prescription device for the treatment of inoperable liver tumours. It is a minimally invasive treatment that delivers high doses of high-energy beta radiation directly to the tumours.

This therapy is called Selective Internal Radiation Therapy (SIRT) and is performed, using minimally invasive surgical techniques, by an interventional radiologist.

SIR-Spheres is approved for the treatment of inoperable liver tumours in the European Union.

For further information please visit

Learn more about Sirtex in our interactive virtual booth

*SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd






Shionogi Europe is committed to applying our patient-first approach in everything we do to develop innovative medicines. Our research-led culture is defined by a distinct openness and close partnership approach to discovering and developing medicines addressing serious unmet medical needs. Our development approach goes hand-in-hand with the collaborative drug discovery process that lies at the heart of Shionogi and our people.

We are working with you to change the fight against cancer. Our best-in-class portfolio enables personalised interventional strategies – innovative solutions that are supported by robust evidence and unparalleled educational partnership.


At Terumo Interventional Systems, we constantly work to refine and perfect our products so that physicians can do more. That is why we support great thinking that pushes back the boundaries of our field. We are committed to innovation that embraces intricacies and complexities. Our exceptional tools, such as LifePearl, (drug eluting beads for the treatment of HCC and CRC) Occlusafe (microcatheter for optimising conventional TACE)  and QuiremSpheres (Selective Internal Radiation)  together with an education programs, including dedicated Interventional Oncology workshops, empower physicians with the confidence they need to perform ever-more challenging procedures and spark progress. We look forward to meeting you at HCC UK 2021.

Thank you for our conference sponsors, who have had no input into the agenda, with the exception of the sponsored symposium sessions, for which the sponsoring companies are fully responsible.